Skip to main content
Funded Studies

Erik M. Schwiebert, PhD

CEO and Chief Scientific Officer at DiscoveryBioMed, Inc.

Location: Birmingham, AL United States

Dr. Erik Schwiebert is founding CEO and chief scientific officer of DiscoveryBioMed, Inc. (DBM), a life sciences and biotechnology company in Birmingham, Alabama that is focused on leveraging diseased and healthy human cells as platform technologies for ‘humanized’ drug discovery and lead therapeutic asset profiling. Dr. Schwiebert is a cell biologist, physiologist and pathophysiologist who uses a blend of applied science and basic science for drug discovery projects using bioassays in human cells. DBM has multiple preclinical hit-to-lead/lead compound programs focused on specific disorders such as Parkinson’s disease ad autoimmune and renal diseases, including niche human genetic diseases. DBM also performs human cell culture creation, human cell-based drug discovery, and human cell-based bioassays on lead therapeutic assets as contract research services

Associated Grants

  • Preclinical Development of Immune-inhibiting Small Molecules as Therapeutics for Parkinson’s Disease


We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.